Retraction
Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
Paper Information
Record ID:
36210
Author(s):
Journal:
Publication Date:
December 24, 2020
Retraction Date:
February 05, 2022
(3.8 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institutions:
- School of Medicine, Wayne State University, Detroit, Michigan, USA
- Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA
- FibroGen, Inc., San Francisco, California, USA
- AstraZeneca, Gaithersburg, Maryland, USA
- AstraZeneca, Mölndal, Sweden
Countries:
Article Type:
Publisher:
Elsevier
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (35)
35
Total Citations13
Post-Retraction(37.1%)
22
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
1
Within 30 days
9
Within 1 year
2
After 2+ years
1055
Days since retraction (latest)
Prolyl hydroxylase domain inhibitors prevent kidney crystal formation by suppressing inflammation
Kengo Kawase, Shuzo Hamamoto, Rei Unno et al. (6 authors)
Urolithiasis
Published: Dec 2024
2 citations
2 citations
1055 days after retraction
Prolyl hydroxylase domain inhibitors prevent kidney stone formation by suppressing inflammation
Kengo Kawase, Shuzo Hamamoto, Rei Unno et al. (6 authors)
Research Square (Research Square)
Open Access
Published: Nov 2024
1004 days after retraction
Comparison between the influence of roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis
Shuiqin Cheng, Tingting Zhou, Le Yu et al. (10 authors)
Frontiers in Medicine
Open Access
Published: Jun 2023
3 citations
3 citations
488 days after retraction
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Elaine Ku, Lucia Del Vecchio, Kai‐Uwe Eckardt et al. (64 authors)
Kidney International
Open Access
Published: May 2023
77 citations
77 citations
474 days after retraction
Management of Anemia in Peritoneal Dialysis Patients
Nupur Gupta, Jay B. Wish
Springer eBooks
Published: Jan 2023
1 citation
1 citation
330 days after retraction
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Daniel W. Coyne, Ajay Singh, Renato D. Lópes et al. (14 authors)
Clinical Journal of the American Society of Nephrology
Open Access
Published: Aug 2022
30 citations
30 citations
192 days after retraction
Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?
Iain C. Macdougall
Current Opinion in Nephrology & Hypertension
Published: Jul 2022
10 citations
10 citations
160 days after retraction
HIF-PHIs for Anemia Management in CKD
Wendy McCallum, Daniel E. Weiner
Clinical Journal of the American Society of Nephrology
Open Access
Published: Jul 2022
9 citations
9 citations
150 days after retraction
Daprodustat in renal anaemia: changing the response to cellular hypoxia, but is it a game changer?
Michael Sullivan, Patrick B. Mark
Cardiovascular Research
Open Access
Published: Apr 2022
79 days after retraction
Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial
Wen Yu-min, Yang Xu, Hui Tian et al. (6 authors)
Frontiers in Medicine
Open Access
Published: Apr 2022
5 citations
5 citations
58 days after retraction
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients
Ajay Singh, Borut Čižman, Kevin Carroll et al. (23 authors)
JAMA Internal Medicine
Open Access
Published: Apr 2022
57 citations
57 citations
58 days after retraction
Anemia of chronic kidney disease: Will new agents deliver on their promise?
Tarek Souaid, Jonathan J. Taliercio, James Simon et al. (5 authors)
Cleveland Clinic Journal of Medicine
Open Access
Published: Apr 2022
4 citations
4 citations
55 days after retraction
Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease
Arash Rashidi, Pranav S. Garimella, Abdullah Al-Asaad et al. (6 authors)
Advances in Chronic Kidney Disease
Published: Mar 2022
5 citations
5 citations
24 days after retraction
Disturbance of Hypoxia Response and Its Implications in Kidney Diseases
Zuo‐Lin Li, Bin Wang, Yi Wen et al. (6 authors)
Antioxidants and Redox Signaling
Published: Jan 2022
7 citations
7 citations
17 days before retraction
Management of Anemia in Peritoneal Dialysis Patients
Nupur Gupta, Jay B. Wish
Springer eBooks
Published: Jan 2022
35 days before retraction
Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
David Czock, Frieder Keller
Clinical Pharmacokinetics
Open Access
Published: Dec 2021
28 citations
28 citations
53 days before retraction
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
Ajay Singh, Kevin Carroll, Vlado Perkovic et al. (22 authors)
New England Journal of Medicine
Open Access
Published: Nov 2021
77 citations
77 citations
92 days before retraction
Roxadustat for the treatment of anemia in patients with <scp>lower‐risk</scp> myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study
David H. Henry, John A. Glaspy, Rosemary Harrup et al. (12 authors)
American Journal of Hematology
Open Access
Published: Nov 2021
50 citations
50 citations
96 days before retraction
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease
Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Expert Opinion on Pharmacotherapy
Published: Oct 2021
17 citations
17 citations
105 days before retraction
Perbandingan efektivitas dan keamanan antara roxadustat dan epoetin alfa sebagai terapi anemia pada pasien yang menjalani hemodialisis reguler: meta analisis
Kadek Wisnu Segara Karya, Ni Luh Parameswari Praptika, Nyoman Yudia Trianadewi Nurbudhi et al. (4 authors)
Intisari Sains Medis
Open Access
Published: Oct 2021
106 days before retraction
Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages
Akira Mima
European Journal of Pharmacology
Open Access
Published: Oct 2021
55 citations
55 citations
107 days before retraction
Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
Jonathan Barratt, Władysław Sułowicz, Michael Schömig et al. (7 authors)
Advances in Therapy
Open Access
Published: Sep 2021
61 citations
61 citations
144 days before retraction
Cerebrovascular Complications of Anemia
Ana Catarina Fonseca, Daniela P. Silva, Joana Infante et al. (4 authors)
Current Neurology and Neuroscience Reports
Published: Sep 2021
10 citations
10 citations
155 days before retraction
A Scalable Synthesis of Roxadustat (FG-4592)
Ondřej Píša, S. Rádl, Igor Čerňa et al. (4 authors)
Organic Process Research & Development
Published: Aug 2021
8 citations
8 citations
172 days before retraction
Cardiovascular Safety of Roxadustat in CKD Anemia
Wolfgang C. Winkelmayer, Carl P. Walther
Clinical Journal of the American Society of Nephrology
Open Access
Published: Aug 2021
4 citations
4 citations
188 days before retraction
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation
Jay B. Wish, Kai‐Uwe Eckardt, Csaba P. Kövesdy et al. (6 authors)
American Journal of Kidney Diseases
Open Access
Published: Jul 2021
17 citations
17 citations
192 days before retraction
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era
Gary H. Lyman, Nicole M. Kuderer, Matti Aapro
Frontiers in Oncology
Open Access
Published: Jul 2021
17 citations
17 citations
212 days before retraction
Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
Jay B. Wish
Kidney International Reports
Open Access
Published: Jun 2021
2 citations
2 citations
227 days before retraction
Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
Jay B. Wish
Kidney International Reports
Open Access
Published: Jun 2021
16 citations
16 citations
241 days before retraction
Did Roxadustat's Results Change from Blockbuster to Lackluster?
Eric Seaborg
Kidney News
Published: Jun 2021
249 days before retraction
A new paradigm in treating patients with chronic kidney disease and anaemia after a journey lasting more than 35 years
Francesco Locatelli, Lucia Del Vecchio
Nephrology Dialysis Transplantation
Published: May 2021
262 days before retraction
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
Robert Provenzano, Evgeny Shutov, Л. Ф. Еремеева et al. (14 authors)
Nephrology Dialysis Transplantation
Published: Feb 2021
106 citations
106 citations
352 days before retraction
Roxadustat for CKD Anemia – Starting the Jigsaw Puzzle, What Will the Finished Picture Show?
Wolfgang C. Winkelmayer, Carl P. Walther
Kidney International Reports
Open Access
Published: Feb 2021
2 citations
2 citations
364 days before retraction
Iron Therapy in Chronic Kidney Disease: Days of Future Past
Kuo‐Hua Lee, Yang Ho, Der‐Cherng Tarng
International Journal of Molecular Sciences
Open Access
Published: Jan 2021
17 citations
17 citations
381 days before retraction
HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety
Simon D. Roger, Daniel W. Coyne
American Journal of Nephrology
Open Access
Published: Jan 2021
8 citations
8 citations
400 days before retraction
Quick Stats
Total Citations:
35
Years Since Retraction:
3.8 years
Open Access:
Yes
Last Checked:
Jul 24, 2025